Abstract
World Health Organization estimates that around 48,000 new instances of cancer were diagnosed in Malaysia every year and 17.3% of it is breast cancer. Some treatments such as surgery, radiation, chemotherapy, hormone therapy, targeted therapy, and immunotherapy are frequently used with their side effects. Therefore, using natural products from the Prismatomeris genus such as P.glabra to treat breast cancer is safer and has been the subject of much inquiry as it is believed to have anticancer substances. This study was conducted to clarify the molecular mechanisms underlying the action of the Epigallogatechin gallate (EGCG) identified from P. glabra on MCF-7 the cell line. The ten most significant associated expressed genes with their expression level were identified based on Transcriptomic Profile in EGCG-treated MCF-7. Based on these data, the mechanism of the signalling pathway and the role of the putative genes were evaluated using the Reactome database. Then, the protein interaction was determined using STRING software. The associated genes with their expression level and the mechanism of the signalling pathway were determined based on the p-value. The result from the Transcriptomic Profile in EGCG-treated MCF-7 showed differentially expressed aberrant genes with significant association (p-value < 0.05). The dysregulated expressed genes were classified according to upregulated and downregulated (volcano plot) genes including the ASS1 (2.75E-23), ID1 (9.70E-18), LCP1 (3.20E-15), TAGLN (1.14E-14), ELOVL6 (2.70E-13), ID2 (1.20E-12), DDIT3 (3.76E-12), ACSL3 (5.05E-11), SREBF1 (1.70E-09) and SNORA109 (2.24E-08). The study revealed the molecular mechanism of differentially expressed genes in EGCG from P.glabra in treating breast cancer such as the MAPK signalling pathway and interaction among the proteins which provide insight into the potential usage of medicinal plants in developing personalized medicine for better treatment for the patient with breast cancer in ensuring better patient healthcare.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
